File(s) not publicly available
Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014
journal contributionposted on 2023-05-19, 09:36 authored by Louise CooleyLouise Cooley, Dendle, C, Wolf, J, Teh, BW, Chen, SC, Boutlis, C, Thursky, KA
Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.
Publication titleInternal Medicine Journal
Department/SchoolTasmanian School of Medicine
PublisherBlackwell Science Asia
Place of publicationAustralia